Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.

Pfizer will discuss the data on its CDK4/6 inhibitor plus anti-HER2 and endocrine therapy with regulators, hoping it will become a new standard option.

The Phase 3 PATINA Trial shows that adding palbociclib (IBRANCE®) to standard maintenance therapy significantly extends ...

The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to support it. Meanwhile, the makers of these drugs have been reporting double-digit ...

Pfizer (PFE) and Alliance Foundation Trials announced results from the Phase 3 PATINA trial demonstrating that the addition ...

The early results presented before the San Antonio Breast Cancer Symposium saw an increased rate of progression-free survival ...

US pharma giant Pfizer and Alliance Foundation Trials (AFT) have announced results from the Phase III PATINA trial.

Pfizer touts Ibrance’s status as a standard of care in HR-positive, HER2-negative metastatic breast cancer. Now the company ...

Pfizer's PATINA trial highlights IBRANCE's potential in HR+/HER2+ metastatic breast cancer, improving outcomes with a ...

Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence ...

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...

StreamUnlimited Engineering has partnered with Fraunhofer IIS to demonstrate upHear Flexible Rendering at CES 2025.This exciting technology delivers optimized sound quality and allows for an immersive ...